Reportlinker Adds Triple Analysis: Leukemia, Prostate Cancer and Apoptosis

NEW YORK, May 3, 2011 /PRNewswire/ — Reportlinker.com announces
that a new market research report is available in its
catalogue:

Triple Analysis: Leukemia, Prostate Cancer and
Apoptosis

http://www.reportlinker.com/p0284700/Triple-Analysis-Leukemia-Prostate-Cancer-and-Apoptosis.html

This triple analysis focuses on cancer drug development
strategies in both Leukemia and Prostate Cancer and by the
mechanism/target/effect of Apoptosis. Each of these three
individual parts is evaluated according to standardized criteria in
a five pillar pipeline drug assessment methodology to compare drug
development strategies in oncology. This makes it easy to find and
compare analysis not only within one single cancer focus area but
also between different areas.

Below is a short synopsis of each part included in this
report:

Part I: Leukemia

The leukemia report part comprises defined and up to date
development strategies for 313 leukemia drugs within the portfolio
of 186 investigators, from Ceased to Marketed. This part
extensively analyses their 204 identified drug targets, organized
into 193 drug target strategies, and assesses them in eight
different compound strategies and eight subindications of
leukemia.

This part is based on the following publication:

A Decision Support Tool for Optimizing The Leukemia Pipeline:
From Research and Development to Market

Part II: Prostate Cancer

The prostate cancer report part comprises defined and up to date
development strategies for 346 prostate cancer drugs within the
portfolio of 198 investigators, from Ceased to Marketed. This
report part extensively analys

‘/>”/>

SOURCE